Quoin Pharma Files Proxy Statement

TL;DR

Quoin Pharma (QNRX) filed its DEF 14A proxy statement. Standard stuff.

AI Summary

Quoin Pharmaceuticals, Ltd. filed a Definitive Proxy Statement (DEF 14A) on October 24, 2024, for the fiscal year ending December 5, 2024. The company, formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd., is headquartered in Kfar Saba, Israel. This filing is related to the company's proxy solicitation process.

Why It Matters

This filing is a standard regulatory requirement for public companies, providing shareholders with information necessary to vote on company matters.

Risk Assessment

Risk Level: low — This filing is a routine proxy statement and does not contain new material financial or operational information that would inherently increase risk.

Key Numbers

• 20241024 — Filing Date (Date the DEF 14A was filed with the SEC.)
• 20241205 — Report Period End Date (The fiscal year end date for which the proxy statement is relevant.)

Key Players & Entities

• Quoin Pharmaceuticals, Ltd. (company) — Registrant
• Cellect Biotechnology Ltd. (company) — Former company name
• Cellect Biomed Ltd. (company) — Former company name
• 23 Hata'as Street, Kfar Saba, L3 44425 (location) — Business and mailing address

FAQ

Key Financial Figures

• $14,500 — reed to pay Kingsdale Advisors a fee of $14,500 plus reimburse them for certain out-of-

Filing Documents

• tm2425968-2_def14a.htm (DEF 14A) — 676KB
• lg_quoin-4clr.jpg (GRAPHIC) — 13KB
• lc_companytsr-4clr.jpg (GRAPHIC) — 65KB
• lc_netloss-4clr.jpg (GRAPHIC) — 58KB
• px_24quoinproxy1pg01-bw.jpg (GRAPHIC) — 275KB
• px_24quoinproxy1pg02-bw.jpg (GRAPHIC) — 210KB
• 0001104659-24-111010.txt ( ) — 1470KB

FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2023

FINANCIAL STATEMENTS FOR THE YEAR ENDED DECEMBER 31, 2023 33

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 34 PAY VERSUS PERFORMANCE 41 BENEFICIAL OWNERSHIP OF SECURITIES BY CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 44 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 45 SHAREHOLDER PROPOSALS 46 HOUSEHOLDING OF PROXY MATERIALS 46 OTHER BUSINESS 46 ANNUAL REPORT 47 TABLE OF CONTENTS PROXY STATEMENT FOR THE 2024 ANNUAL GENERAL MEETING OF SHAREHOLDERS Thursday, December 5, 2024 PROXY STATEMENT SUMMARY This summary highlights information contained elsewhere in this proxy statement. It does not contain all of the information you should consider, and you should read the entire proxy statement carefully before voting. References in this proxy statement to the "Company," "Quoin," "Quoin Ltd.," "we," "us," and "our" refer to Quoin Pharmaceuticals Ltd., an Israeli company. The Notice of Annual General Meeting of Shareholders, proxy statement and a proxy card or voting instruction form, as applicable, are being distributed and made available to the holders of our ordinary shares, as well as holders of our ordinary shares that are represented by American Depositary Shares ("ADSs"), collectively referred to as "shareholders," starting on or about October 24, 2024. Our principal executive offices are located at 42127 Pleasant Forest Ct., Ashburn, VA 20148. Annual Meeting Information Date and Time: Thursday, December 5, 2024, beginning at 12:00 p.m., US Eastern Time Meeting Place: Offices of Blank Rome LLP located at One Logan Square, Philadelphia, PA 19103 Record Date: October 21, 2024 Voting: Each ordinary share is entitled to one vote per share on all matters presented at the Annual Meeting. Each ADS represents one of our ordinary shares. It is important that your shares be represented and voted at the Annual Meeting. Shareholders should vote by marking, signing and dating the accompanying proxy card if you hold ordinary shares, or voting instruction form if you hold ordinary shares represented by

View Full Filing

View this DEF 14A filing on SEC EDGAR